Results 11 to 20 of about 8,545 (211)

Conventional type 1 dendritic cells (cDC1) in cancer immunity

Biology Direct, 2023
Cancer immunotherapy, alone or in combination with conventional therapies, has revolutionized the landscape of antineoplastic treatments, with dendritic cells (DC) emerging as key orchestrators of anti-tumor immune responses.
Peng Liu, Liwei Zhao, Guido Kroemer, Oliver Kepp   +3 more
doaj   +5 more sources

Importance of EMT Factor ZEB1 in cDC1 “MutuDC Line” Mediated Induction of Th1 Immune Response

Frontiers in Immunology, 2018
The role of Epithelial to Mesenchymal Transition (EMT) factor Zeb1 is well defined in metastasis and cancer progression but it's importance in dendritic cells (DCs) is unexplored until now. For the first time we report here that Zeb1 controls immunogenic
Sunil Kumar Raghav, Hans Acha-Orbea, Marianna M Koga   +2 more
exaly   +4 more sources

Supplementary Figure from cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1

, 2023
Supplementary Figure from cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host ...
Kenneth M. Murphy, Theresa L. Murphy, Robert D. Schreiber, Tian-Tian Liu, Jing Chen, Sunkyung Kim, Xiao Huang, Renee Wu, Feiya Ou, Ray A. Ohara, Stephen T. Ferris   +10 more
openaire   +2 more sources

IL-6 selectively suppresses cDC1 specification via C/EBPβ [PDF]

Journal of Experimental Medicine, 2023
Cytokines produced in association with tumors can impair antitumor immune responses by reducing the abundance of type 1 conventional dendritic cells (cDC1), but the mechanism remains unclear. Here, we show that tumor-derived IL-6 generally reduces cDC development but selectively impairs cDC1 development in both murine and human systems through the ...
Sunkyung Kim, Jing Chen, Suin Jo, Feiya Ou, Stephen T. Ferris, Tian-Tian Liu, Ray A. Ohara, David A. Anderson, Renee Wu, Michael Y. Chen, William E. Gillanders, William E. Gillanders, Theresa L. Murphy, Kenneth M. Murphy   +13 more
openaire   +4 more sources

Antigen presentation requirements for effective cDC1-based cancer immunotherapy. [PDF]

J Immunol
Abstract Type 1 conventional dendritic cells (cDC1s) are important for generating and sustaining antitumor immunity. Accordingly, the abundance of cDC1s in human tumors correlates with improved outcomes in cancer. Capitalizing on this role, we previously demonstrated that vaccination with in vitro
Pineda JE, Minowa T, Shen L, Zhou Y, Dyevoich A, Patel B, Schneider SM, Keshari S, Saha A, Riba MN, Wang J, Watowich SS, Gubin MM.   +12 more
europepmc   +4 more sources

Development and migration of cDC1 in the spleen

Precursor of dendritic cells (preDCs) develop in the bone marrow and continuously seed in tissues where preDCs further differentiate and migrate to and within secondary lymphoid organs to orchestrate adaptive immunity. Where preDCs seed the splenic red pulp, locally develop into type 1 conventional dendritic cells (cDC1s) and migrate to the white pulp ...
Labios, Reuben Jacob
openaire   +3 more sources

Intratumoral delivery of FLT3L with CXCR3/CCR5 ligands promotes XCR1+ cDC1 infiltration and activates anti-tumor immunity

Nature Communications
Tumor infiltration by XCR1⁺ conventional dendritic cells (cDC1) correlates strongly with favorable prognosis and improved responses to immunotherapy. Yet, tumor-driven immunosuppressive programs restrict efficient cDC1 recruitment, highlighting the need ...
Louise Gorline, Fillipe Luiz Rosa do Carmo, Pierre Bourdely, Jérémie Bornères, Nathan Vaudiau, Aurélie Semervil, Mathias Vetillard, Aboubacar Sidiki K Coulibaly, Natacha Jugniot, Agathe Ok, Mathilde Bausart, Oriane Fiquet, Marine Andrade, Dicken Fardol, Ikrame Haddar, Zeina Abou Nader, Judith Weber, Hannah Theobald, Matthieu Collin, Joseph Calmette, Giorgio Anselmi, Flavia Fico, Florent Ginhoux, Laleh Majlessi, Emmanuel L. Gautier, Loredana Saveanu, Julie Helft, Marc Dalod, Mathilde Dusseaux, James P. Di Santo, Stéphanie Hugues, Pierre Guermonprez   +31 more
doaj   +2 more sources

CD4 + helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment [PDF]

Nature Communications, 2023
The presence of classical type 1 dendritic cells (cDC1) positively influences prognosis in cancer, but their intricate networking with the various T cell types found in the tumour microenvironment is not fully appreciated. Here the authors show that cDC1
Xin Lei, Indu Khatri, Tom de Wit, Iris de Rink, Marja Nieuwland, Ron Kerkhoven, Hans van Eenennaam, Chong Sun, Abhishek D. Garg, Jannie Borst, Yanling Xiao   +10 more
doaj   +2 more sources

Vaccination against neoantigens induced in cross-priming cDC1 in vivo

Cancer Immunology, Immunotherapy
AbstractThe conventional type 1 dendritic cells (cDC1) play a pivotal role in protective immunity against pathogens and cancer. However, their low frequency in the blood and tissues limits their use in immune therapy. We have recently described a method to vaccinate against neoantigens that are induced in tumor cells by targeted delivery of a TAP siRNA
Emily S. Clark, Ana Paula Benaduce, Wasif N. Khan, Olivier Martinez, Eli Gilboa   +4 more
openaire   +3 more sources

Who on IRF are you? IRF8 deficiency redirects cDC1 lineage commitment

Trends in Immunology, 2022
Interferon regulatory factor 8 (IRF8) has long been associated with conventional dendritic cell type I (cDC1) development. In a recent study, Lança et al. demonstrate that IRF8 is also crucial in cells already committed to the cDC1 lineage. Here, deletion of IRF8 from the XCR1-expressing pre-cDC1 stage onward leads to a loss of commitment and ...
Waller, Kathryn, Scott, Charlotte L.
openaire   +3 more sources